Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor

Donald R Nixon,1– 4 Nicholas Flinn1 1Trimed Eye Centre, Barrie, Ontario, L4M 4S5, Canada; 2Department of Surgery, Royal Victoria Regional Health Centre, Barrie, Ontario, Canada; 3Department of Surgery, Soldiers Memorial Hospital, Orillia, Ontario, Canada; 4Department of Surgery, Northern O...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nixon DR, Flinn N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	contrast sensitivity residual deficit functional impairment Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/04aafed9fc7c4a2aaa05af4e4c8d2e2f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:04aafed9fc7c4a2aaa05af4e4c8d2e2f
record_format	dspace
spelling	oai:doaj.org-article:04aafed9fc7c4a2aaa05af4e4c8d2e2f2021-12-02T13:31:53ZVisual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor1177-5483https://doaj.org/article/04aafed9fc7c4a2aaa05af4e4c8d2e2f2021-04-01T00:00:00Zhttps://www.dovepress.com/visual-function-for-driving-in-diabetic-macular-edema-and-retinal-vein-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Donald R Nixon,1– 4 Nicholas Flinn1 1Trimed Eye Centre, Barrie, Ontario, L4M 4S5, Canada; 2Department of Surgery, Royal Victoria Regional Health Centre, Barrie, Ontario, Canada; 3Department of Surgery, Soldiers Memorial Hospital, Orillia, Ontario, Canada; 4Department of Surgery, Northern Ontario School of Medicine NOSM, Sudbury, Ontario, CanadaCorrespondence: Donald R NixonTrimed Eye Centre Barrie Ontario, 190 Cundles Road East Suite 100c, Barrie, Ontario, L4M 4S5, CanadaTel +1 705 737 3737Email Trimedeyedoc@gmail.comPurpose: What is the level of visual function in patients with diabetic macular edema (DME) and retinal vein occlusion (RVO) post-stabilization with anti-vascular endothelial growth factor?Patients and Methods: This observational non-controlled single center study evaluated visual function in two patient populations with macular edema 25 with diabetic macular edema and 25 with retinal vein occlusion treated following standard protocol of anti-VEGF therapy post- stabilization.Results: A total of 68 eyes from 50 patients were analyzed including 18 bilateral and 7 unilateral diabetic macular edema, 14 patients with central and 11 with branch retinal vein occlusion. The mean age was 69± 11 years and 64% were male. In the RVO group: LogMAR BCVA was 0.12± 0.13 compared to the unaffected eye 0.04± 0.05 (P=< 0.01), contrast sensitivity in the treated eye was 1.69± 0.21 log units compared to 1.84± 0.15 log units in the unaffected eye (p=< 0.01), the ganglion cell volume was 0.88± 0.15 mm3 in the treated eye compared to 1.04± 0.1 mm3 in the unaffected eye (P=< 0.01). In the diabetic macular edema group: LogMAR BCVA was 0.17± 0.13, contrast sensitivity in the treated eye was 1.16± 0.21 log units compared to the normal population 1.92± 0.8 log units (p=< 0.01), the ganglion cell volume was 0.94± 0.14 mm3 in the treated eye compared to 1.03± 0.12 mm3 in the normal population (P=< 0.001). In both groups a majority of treated eyes retained visual acuity ≥+0.4 LogMAR (diabetic macular edema 95%, RVO 96%) however contrast sensitivity was more than two standard deviations below the normal population mean in a majority of treated eyes in both groups (diabetic macular edema 88% RVO 64%).Conclusion: Impairment in contrast sensitivity in both groups could impact activities of daily living including driving and should prompt questions about how we advise patients regarding their level of function and the potential limitations/restrictions that should be placed on such activities.Keywords: contrast sensitivity, residual deficit, functional impairmentNixon DRFlinn NDove Medical Pressarticlecontrast sensitivityresidual deficitfunctional impairmentOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1659-1666 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	contrast sensitivity residual deficit functional impairment Ophthalmology RE1-994
spellingShingle	contrast sensitivity residual deficit functional impairment Ophthalmology RE1-994 Nixon DR Flinn N Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
description	Donald R Nixon,1– 4 Nicholas Flinn1 1Trimed Eye Centre, Barrie, Ontario, L4M 4S5, Canada; 2Department of Surgery, Royal Victoria Regional Health Centre, Barrie, Ontario, Canada; 3Department of Surgery, Soldiers Memorial Hospital, Orillia, Ontario, Canada; 4Department of Surgery, Northern Ontario School of Medicine NOSM, Sudbury, Ontario, CanadaCorrespondence: Donald R NixonTrimed Eye Centre Barrie Ontario, 190 Cundles Road East Suite 100c, Barrie, Ontario, L4M 4S5, CanadaTel +1 705 737 3737Email Trimedeyedoc@gmail.comPurpose: What is the level of visual function in patients with diabetic macular edema (DME) and retinal vein occlusion (RVO) post-stabilization with anti-vascular endothelial growth factor?Patients and Methods: This observational non-controlled single center study evaluated visual function in two patient populations with macular edema 25 with diabetic macular edema and 25 with retinal vein occlusion treated following standard protocol of anti-VEGF therapy post- stabilization.Results: A total of 68 eyes from 50 patients were analyzed including 18 bilateral and 7 unilateral diabetic macular edema, 14 patients with central and 11 with branch retinal vein occlusion. The mean age was 69± 11 years and 64% were male. In the RVO group: LogMAR BCVA was 0.12± 0.13 compared to the unaffected eye 0.04± 0.05 (P=< 0.01), contrast sensitivity in the treated eye was 1.69± 0.21 log units compared to 1.84± 0.15 log units in the unaffected eye (p=< 0.01), the ganglion cell volume was 0.88± 0.15 mm3 in the treated eye compared to 1.04± 0.1 mm3 in the unaffected eye (P=< 0.01). In the diabetic macular edema group: LogMAR BCVA was 0.17± 0.13, contrast sensitivity in the treated eye was 1.16± 0.21 log units compared to the normal population 1.92± 0.8 log units (p=< 0.01), the ganglion cell volume was 0.94± 0.14 mm3 in the treated eye compared to 1.03± 0.12 mm3 in the normal population (P=< 0.001). In both groups a majority of treated eyes retained visual acuity ≥+0.4 LogMAR (diabetic macular edema 95%, RVO 96%) however contrast sensitivity was more than two standard deviations below the normal population mean in a majority of treated eyes in both groups (diabetic macular edema 88% RVO 64%).Conclusion: Impairment in contrast sensitivity in both groups could impact activities of daily living including driving and should prompt questions about how we advise patients regarding their level of function and the potential limitations/restrictions that should be placed on such activities.Keywords: contrast sensitivity, residual deficit, functional impairment
format	article
author	Nixon DR Flinn N
author_facet	Nixon DR Flinn N
author_sort	Nixon DR
title	Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
title_short	Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
title_full	Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
title_fullStr	Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
title_full_unstemmed	Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
title_sort	visual function for driving in diabetic macular edema and retinal vein occlusion post-stabilization with anti-vascular endothelial growth factor
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/04aafed9fc7c4a2aaa05af4e4c8d2e2f
work_keys_str_mv	AT nixondr visualfunctionfordrivingindiabeticmacularedemaandretinalveinocclusionpoststabilizationwithantivascularendothelialgrowthfactor AT flinnn visualfunctionfordrivingindiabeticmacularedemaandretinalveinocclusionpoststabilizationwithantivascularendothelialgrowthfactor
_version_	1718392834592079872

Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor

Ejemplares similares